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Concurrent chemoradiotherapy is considered the standard treatment for the locally advanced cancer cervix 
(LACC).Radiotherapy is usually administered by a three-dimensional conformal external beam(3DCRT EBRT) 
approach to whole pelvis to a minimum dose of 45Gy, followed by a brachytherapy ( BT)boost to give 
additional dose to the gross tumor within the cervix and parametria. High dose rate (HDR) brachytherapy is 
commonly administered with intracavitory applicator. HDR BT allows delivery of a high radiation dose to the 
tumor site with rapid fall off so protect normal tissue. Besides, less target motion compared to EBRT. However, 
several drawbacks exist including invasive technique, pain, requiring spinal or general anesthesia and operative 
risks such as uterine perforation, infection, and bleeding. Due to the above risks, we tried to assess the 
possibility of using high technique  EBRT to replace the BT boost  in patients who are either medically unfit for 
or refuse a brachytherapy boost. we tried to achieve a similar dose distribution with comparable or improved 
normal tissue sparing to that seen in previously treated HDR BT plans at our institution. Dosimetric comparison 
between high technique of external beam radiotherapy volumetric arc therapy (VMAT) and high technique 
Computer topography (CT) guided HDR BT.Ten patients were selected with LACC, representing typical 
clinical situations according to initial tumor extension and response after EBRT. A boost was given by 
intracavitary CT guided HDR BT. High risk clinical target volume (HR CTV), bladder, rectum, sigmoid and 
small bowel were delineated.  
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Planning was done using Sagi planning system and was manually optimized with respect to organ dose limits. A 
VMAT planning was created using the variance planning system and a margin of 5mm were added to the CTV 
to create the target planning target volume (PTV).The inversely planned VMAT was challenged to deliver the 
highest possible doses to PTVs while respecting D2cc limits from BT, assuming the same fractionation (7 Gy in 
3 fractions). When VMAT was limited to D2cc from BT, the D90 for the PTV in VMAT boost was lower than 
received by the HR CTV in the BT boost (6.3Gy vs. 6.9Gy, p value 0.037). Mean volume of the PTV in VMAT 




).The dose to the organ at risks (OARs) was 
comparable.D2cc was higher in VMAT for bladder, sigmoid and rectum (5.6Gy, 0.51, 5.5Gy vs. 4.3Gy, 0.33, 
3.9Gy) while D2cc for the small bowel in BT was higher compared to the VMAT (4.1Gy vs. 1.94Gy    ).The 
VMAT had comparable target coverage and potential for improved sparing of most normal tissues compared to 
brachytherapy boost. It is an option that exists for patients who refuse BT or can’t tolerate it or in case of non 
availability of BT or non working machine. However, this is a dosimetric comparison that needs larger number 
of patients and further application to study the drawbacks that might exist for the VMAT use.  
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1. Introduction 
CCR is considered the standard treatment of LACC.The radiotherapy treatment consist of EBRT and BT boost. 
Although using HDR brachytherapy provide a unique pear shaped dose distribution with steep dose gradients, 
they also contain certain limitations concerning patient specific source configurations, cause more patient 
discomfort, and are subject to errors due to applicator movement or alignment between fractions, insertion of the 
device, and image acquisition [1]. VMAT was first introduced in 2007 and described as a novel radiation 
technique that allowed the simultaneous variation of three parameters during treatment delivery, i.e. gantry 




VMAT showed a great potential for producing highly conformal doses to treatment volumes while sparing 
OARs [3].On the other hand; it was unable to deliver an increased homogenous dose to the PTV while 
appropriately sparing the OARs. VMAT could potentially be an alternative option for duplicating traditional 
brachytherapy dose distributions for patients in need of brachytherapy who are unable to undergo this 
treatment modality [3]. Toxicity to OARs should always be considered when using any EBRT technique to treat 
those who are unable to receive BT treatment with the gastrointestinal tracks toxicity being the main recorded 
toxicity
 
[1]. Also the considerations for target motion and delineation made the VMAT technique limited 
compared to the traditional BT technique [4]. 
2. Methods and Materials 
Ten patients were selected with locally advanced cervix cancer, representing typical clinical situations according 
to initial tumor extension and response after EBRT. A boost was given by intracavitary CT guided HDR 
brachytherapy. High risk clinical target volume (HR-CTV), bladder, rectum, and small bowel were delineated. 
Planning was done using Sagi planning system and was manually optimized with respect to organ dose limits. A 
VMAT planning was created using the variance planning system and a margin of 5mm were added to the CTV 




to create the target planning target volume (PTV).The inversely planned VMAT was challenged to deliver the 
highest possible doses to PTVs while respecting D2cc limits from BT, assuming the same fractionation (7 Gy in 
3 fractions).  
-The patients received whole pelvis 3D conformal EBRT (45Gy in 25 fractions) with assumption that 
OARs received 100% of the dose. 
-The patients underwent CT guided HDR brachytherapy boost as a part of their treatment protocol. 
2.1. The brachytherapy boost 
-High dose rate brachytherapy (cobalt 60) was used with intracavitary applicator. 
-It was done under spinal or epidural anesthesia. 
-Applicators: Tandem 40/60, Ring (30-35-25). 
-Examination under anesthesia and dilatation of the cervix then insertion of the applicators. 
-A CT scan was done to ensure good application then images were transferred to the CT planning (Sagi 
planning system) where reconstruction was done. 
-Contouring of the: 
 HR CTV (high risk clinical target volume) which is defined by GEC-ESTRO [5] as the area of gross 
residual disease at the time of brachytherapy. It includes the gross disease at the time of implant, the 
entire cervix and any areas clinically suspicious for residual disease.  
 Organ at risk including rectum, urinary bladder and small bowel. 
-Then plan was generated to achieve our goal: 
-A dose to the 90% of the target of 7Gy/f in 3 fractions, (D90=7Gy). 
-A dose to D2cc rectum < 4Gy/f, sigmoid <4Gy/f and urinary bladder <5 Gy/f in each fraction. 
2.2. The VMAT boost was created in the following steps 
 The 10 patients underwent CT imaging before the insertion of the intracavitary brachytherapy 
applicator to avoid any errors in VMATS planning and calculations. 
 The CDs of the 10 patients were received by the planning system (Variance planning system) where 
VMATS planning and dosimtery done. 
 Target volume delineation and organs at risk delineation  were done taking in consideration the 
following: 




-Two different planning system in two separate places  
-The attempts to unify the volumes between the VMATS plans and the brachytherapy plans. 
-HR-CTV in the BT boost was delineated in the VMAT boost as CTV with 5 mm around as a PTV. 
 Two full arcs were used with collimator angel (90-0). 
 Energy used 6 MV. 
 The use of the dose volume histogram to assess the points of comparisons between the two plans. 
 The use of HDR radiobiological dose equivalent worksheets available on the American brachytherapy 
society (ABS) online for dosimetric calculations. 
For the VMAT boost, the same fractionation was assumed as for the BT: 7Gy x 3 fractions to cover the PTV 
after 45 Gy of the EBRT. Inversely planned VMAT was challenged to deliver the highest possible doses to the 
PTV while maintaining the same D2cc limits for bladder, rectum, and sigmoid. Available DVH information 
from brachytherapy was used as input parameters during inverse planning.  The primary target parameter of 
interest was the D90. For VMAT the dose was to be delivered to the PTV structures and not to the CTV as in 
BT.If D90 values of BT could not be reproduced with VMAT, it was aimed to achieve a D90 of 7 Gy for the 
PTV.For treatment plan evaluation, D90 for PTV achieved with VMAT were compared with the HRCTV values 
from advanced BT. Besides, D2cc which was used for treatment planning for the OAR bladder, rectum and 
sigmoid were evaluated. All dosimetric data of different plans were compared with a paired two-tailed Student’s 
t test, and statistical significance was assumed at p < 0.05. 
3. Results 
When VMAT was limited to D2cc from BT, the D90 for the PTV was lower than that received by the HR CTV 
in the  BT boost ( 6.3Gy vs.6.9Gy,p value 0.037    ). Mean volume of the PTV in VMAT is higher than that of 
HR CTV in the BT (89cm
3
 vs.41.7cm3   ). The dose to the organ at risks (OARs) was comparable.D2cc was 












Table 1: Comparison between Brachytherapy and VMAT according to the HR CTV/PTV integral dose and 
parameters 
Parameters Brachytherapy VMAT Z p 
integral dose to 
HRCTV/PTV 
(mean dose x volume) 
    





 Mean ± SD. 191.6±161.6 671.0±185.6 
Median (IQR) 119.8 (101.8-255.6) 653.2 (502.3-752.0) 
Mean dose     





 Mean ± SD. 5.1±1.2 7.5±0.3 
Median (IQR) 5.4 (3.9-6.0) 7.6 (7.4-7.7) 
CTV HR/PTV volume cm3     





 Mean ± SD. 41.7±41.8 89.0±23.6 
Median (IQR) 23.3 (19.8-53.9) 85.8 (66.7-99.1) 
CTVHR/PTV D90     





 Mean ± SD. 6.9±0.80 6.3±0.1 
Median (IQR) 7.0 (6.6-7.2) 6.3 (6.3-6.3) 
Table 2: Comparison between Brachytherapy and VMAT according to the OARs parameters 
Rectum Brachytherapy PTV HRCTV Z p 
Volume      
Min. – Max. 29.9-54.1 29.9-54.1 
- - Mean ± SD. 39.0±8.4 39.0±8.4 
Median (IQR) 36.9 (32.8-43.3) 36.9 (32.8-43.3) 
Mean dose     
Min. – Max. 3.8-7.9 2.0-15.4 
1.784 0.074 Mean ± SD. 5.2±1.2 4.0±4.0 
Median (IQR) 5.3 (4.2-5.6) 2.8 (2.7–3.2) 
D2cc     
Min. – Max. 3.1-4.7 3.8-7.0 
2.599* 0.009* Mean ± SD. 3.9±0.5 5.5±1.0 
Median (IQR) 4.1 (3.3-4.3) 5.3 (4.9-6.3) 
Bladder  Brachytherapy PTV HRCTV Z P 
Volume      
Min. – Max. 9.7-137.3 9.7-137.3   
Mean ± SD. 48.2±35.4 48.2±35.4   
Median (IQR) 42.3 (22.5-55.4) 42.3 (22.5-55.4)   
Mean dose     
Min. – Max. 3.7-7.1 1.7- 4.8 
2.599* 0.009* Mean ± SD. 4.9±1.0 3.2 ± 0.9 
Median (IQR) 4.6 (4.3-5.3) 3.2 (2.8-3.9) 
D2cc     
Min. – Max. 3.2-5.9 4.3 - 6.7 
2.803 0.005* Mean ± SD. 4.3± 0.9 5.6 ± 0.9 
             Median (IQR) 4.0 (3.5-5.3) 5.7 (4.8-6.5) 




Z: Wilcoxon signed ranks test  p: p value for comparing between Brachytherapy and VMAT  
*: Statistically significant at p ≤ 0.05  
4. Discussion 
Considering that all patients received 3 D CRT whole pelvis radiotherapy in a dose of 45Gy in 25 fractions and 
taking in consideration that the OARs received the full dose. The brachytherapy boost received was 7 Gy in 3 
fractions and the same dose with its calculated biological equivalent dose was used for the VMAT boost under 
study. When VMAT was limited to D2cc from BT, the D90 for the PTV was lower significantly than that in the 
BT boost to the HR CTV(6.3Gy vs 6.8Gy with p value 0.037)and variation of the dose with hot areas in BT 
compared to  more homogenous dose in the VMAT ( 5.7Gy-8.1Gy in BT vs 6.2Gy-6.4Gy in the VMAT).This 
coincide with the findings of the study done by Evgeniia Sergeevna 
 
and his colleagues [6] where  the BT boost 
resulted in irradiation of significant target volumes by doses significantly higher than the prescribed dose while 
the VMAT boost significantly improved this situation. Mean volume of the PTV in VMAT is higher than that of 
HR CTV in the BT. The dose to OARs was comparable where the D2cc was higher in VMAT for bladder and 
rectum (5.6Gy& 5.5Gy vs.4.3Gy &3.9Gy for bladder and rectum respectively) while D2cc for the Sigmoid and 
Small bowel in BT were higher compared to the VMAT (3.19Gy and 4.1Gy vs 0.51Gy and 1.94Gy for sigmoid 
and bowel respectively). This coincides with what was found in the trial published by Rajni A.Sethi and his 
colleagues [4] where VMAT had a potential for improved sparing of most normal tissues compared to 
brachytherapy boost. The mean dose to the bladder, rectum and small bowel were lower in the VMAT plan 
compared to the brachytherapy boost with excellent PTV coverage.Also in comparison with the findings of the 
study done by Lila Wali and his colleagues [7]
 
the VMAT achieved significant dose reduction of rectum, 
bladder and sigmoid, as well as superior homogeneous target coverage compared to BT plan. On the other hand, 
VMAT deliverd more radiation exposures to small bowel. It is important to illustrate that the radiation dose and 
coverage depend on target and OAR contouring and motion and this definitely affected by the placement of the 
applicator and Foley catheter.In our study the brachytherapy boost parameters were calculated while the 
intracavitory applicator and packing are in place while the VMAT boost calculation were done before the 
applicator or packing in place and this caused different position and volumes to be irradiated although all 
attempts to unify the volumes irradiated between the two boosts. Also the addition of internal target volume 
(ITV) for the VMAT boost to count for the possible mobility and varying position of the OARs and this will 
possibly affect the dose to the OARs. Besides, the small number of the patients involved in the study and the 
non availability of one working software that can compare the targets and OARs between the BT and VMAT on 
spot. The aim of the VMAT boost application is not to replace the brachytherapy boost but to find an alternative 
accessible option with comparable results.The main advantages of the VMAT boost is to facilitate the treatment 
procedure, reduce patient discomfort results from the BT applicator, reduce the time of irradiation session and 
avoid the anesthesia with all its possible complication. 
5. Conclusion 
The VMAT had comparable target coverage with more homogenous dose and avoidance of hot areas in the 




target and potential for improved sparing of most normal tissues compared to BT boost. It is an option that 
exists for patients who refuse BT or can’t tolerate it or in case of non availability of BT or non working 
machine. Still further dosimetric analysis is needed on larger number of patients and ensure the availability of 
one software that involve both BT and VMAT on spot. Besides further application of the VMAT beyond the 
level of dosimetric study to compare the side effects result from the VMAT compared to the BT boost. 
6. Recommendation 
It is recommended to further apply the VMAT boost on larger number of patients and compare it not only to the 
intracavitory BT but also interstitial BT that can cover the target properly.   
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